Connecting with Patients, Overcoming Uncertainty

John Serio, Partner in the Boston office, co-authored a white paper on Managing the Risks and Regulatory Issues Associated with Successful Pharmaceutical Social Media Monitoring and Marketing.

In the absence of FDA guidance on marketing in blogs, social networks and other social media forms, drug firms’ marketing, compliance and legal staffs must work closely to design initiatives that are sensitive to FDA concerns. This paper provides a framework to clarify and mitigate the risks of a range of social media initiatives

Part I: Social Media, Healthcare and the Pharmaceutical Industry

Part II: An Overview of the Legal and Regulatory Environment for Direct-to-Consumer Promotion

Part III: Social Media Marketing: A Strategic Regulatory Framework